NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of interim Phase I data for indibulin (ZIO-301) at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster entitled “Phase I and pharmacological study of orally administered indibulin in advanced solid tumors” was presented by RL Oostendorp, M.D., Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam. Indibulin is a novel, oral synthetic anti-mitotic agent related to but with a different mechanism than other tubulin-binding drugs that include the widely used taxanes and the vinca alkaloids.
